Med. Weter. 78 (6), 297-303, 2022
full text
PAWEŁ KLIMIUK, WOJCIECH ŁOPUSZYŃSKI, KAMILA BULAK |
Predictive value of topoisomerase IIα immunoreactivity
in canine diffuse large B-cell lymphoma (DLBCL)
and peripheral T-cell lymphoma (PTCL) treated with
a doxorubicin-based chemotherapy protocol |
Topoisomerase IIα (TOPIIα) plays a key role in DNA replication and is a molecular target for TOPIIα inhibitor
chemotherapy. A doxorubicin-based chemotherapy remains the most effective treatment for canine lymphoma,
but there are no clear indications for its use in individual patients. The aim of this study was to assess the
predictive value of TOPIIα expression in the treatment of canine lymphomas with TOPIIα inhibitors. Samples
of formalin-fixed paraffin-embedded lymph nodes from 14 dogs with diffuse large B-cell lymphoma (DLBCL)
and 5 dogs with peripheral T-cell lymphoma (PTCL) treated with a CHOP protocol were immunohistochemically
labelled with anti-TOPIIα. Progression-free survival time (PFS) and overall survival time (OS) were estimated
and compared with TOPIIα expression. Dogs with DLBCL had a higher level of TOPIIα expression compared to
dogs with PTCL. The median PFS for dogs with DLBCL was significantly longer (260 days) than it was for dogs
with PTCL (60 days). In DLBCL dogs with a high TOPIIα expression level, the median PFS was significantly
longer (310 days) then it was in dogs with week or medium TOPIIα expression (51 days). The results of the
study indicate that the immunohistochemical assessment of TOPIIα expression may be a valuable predictive
indicator for anthracycline-based treatment of dogs with malignant lymphoma. |
Keywords: canine lymphoma, immunohistochemistry, topoisomerase IIα, CHOP protocol, chemotherapy |